NEW YORK (GenomeWeb News) – Researchers from the National Cancer Institute have developed a mouse embryonic stem cell-based assay to distinguish deleterious from neutral mutations in the human BRCA1 gene.

The team used the assay to test more than a dozen mutations in the human breast cancer risk gene BRCA1. In each case, the assay appeared to accurately predict which mutations are deleterious in humans and which are neutral.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.